由 Lauren Dubinsky
, Senior Reporter | July 02, 2018
Royal Philips announced a collaboration on Thursday with the life sciences company LabCorp to further the adoption of digital pathology.
“We believe that our collaboration with LabCorp will help to embed and accelerate the use of digital pathology for primary diagnosis in the U.S. and set a new standard in diagnostic services globally,” Marlon Thompson, general manager of Philips Digital Pathology Solutions, told HCB News.
As part of the collaboration, LabCorp will implement the Philips IntelliSite Pathology Solution (PIPS). That will allow the company to incorporate a digitized workflow into its anatomic pathology services, which are a main aspect of its clinical lab and end-to-end drug development services.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
LapCorp will initially implement PIPS in four of its laboratories. It will also work with its interested customers to assess their potential transition to digital pathology.
"LabCorp sees the potential of the Philips digital pathology solution to innovate their business models, with the opportunity for their customers such as a local hospital to have rapid, efficient access to a national network of LabCorp and other pathologists through the U.S., including specialists and sub-specialists," said Thompson. "This will support faster turnaround time of pathology results in critical cases."
PIPS, which scored FDA clearance for primary diagnostic use in April 2017, is an automated digital pathology image creation, viewing and management system. It consists of an ultra-fast scanner, image management system and a display.
It enables pathologists to access tissue images more quickly, collaborate more easily with specialty pathologists around the world and provide faster diagnoses.
Since it’s currently the only digital pathology solution on the market, PIPS is leading the transition from conventional glass slide analysis to reading tissue slides digitally.
“Since the introduction of IntelliSite Pathology Solution, we have seen a major change in mindset by pathologists [who] recognize the fact that they will need to go digital in the near future,” said Thompson. “It is not the discussion anymore if digital pathology will happen, it is about when and how.”